Prospective Single-centre, Open-label Study to Assess the Pharmacokinetics of Cholyl-lysl-fluorescein (NRL972) in Patients with Clinical Evidence for NAFLD: Supporting the Disease Staging Into Fatty Liver Disease Versus NASH
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Cholyl lysyl fluorescein (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Diagnostic use
- Sponsors Norgine
Most Recent Events
- 21 May 2014 New trial record